[1]Ussher, J.R., Drucker, D.J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20, 463–474 (2023). [2]Mitchel L. Zoler. Semaglutide Cuts Cardiovascular Events in Landmark Trial. Medscape. August 08, 2023. 跳转链接:[2]Regina...
[1]Ussher, J.R., Drucker, D.J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20, 463–474 (2023). [2]Mitchel L. Zoler. Semaglutide Cuts Cardiovascular Events in Landmark Trial. Medscape. August 08, 2023. 跳转链接:[2]Regina...
[4] Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial,Retrieved August 10, 2023 from https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301 [5...
[1]Ussher, J. R., & Drucker, D. J. (2023). Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nature reviews. Cardiology, 20(7), 463–474. https://doi.org/10.1038/s41569-023-00849-3 [2]Deanfield, J., Verma, S., Scirica, B. M., ...
“But for all their promise, GLP-1 agonists have raised more questions than they have answered – a hallmark of a true breakthrough.” ——Holden Thorp博士,《科学》期刊总编辑 今日,知名学术期刊《科学》公布胰高血糖素样肽-1(GLP-1)激动剂获选为2023年度科学突破(Science’s 2023 Breakthrough of...
“But for all their promise, GLP-1 agonists have raised more questions than they have answered – a hallmark of a true breakthrough.” ——Holden Thorp博士,《科学》期刊总编辑 12月15日,知名学术期刊《科学》公布胰高血糖素样肽-1(GLP-1)激...
[20]Alfayez OM, Almohammed OA, Alkhezi OS, et al. Indirect comparison of glucagon like peptide‐1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta‐analysis[J...
[1]Ussher, J. R., & Drucker, D. J. (2023). Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nature reviews. Cardiology, 20(7), 463–474. https://doi.org/10.1038/s41569-023-00849-3 [2]Deanfield, J., Verma, S., Scirica, B. M., Kahn...
[8]Sattar N, Lee MMY,Kristensen SL,et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.Lancet Diabetes Endocrinol. 2021;9(10):653-662. ...
[2] Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patientswith diabetes. Eur Heart J, 2023. DOI: 10.1093/eurheartj/ehad192. [3] Ussher JR. et al. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms...